Goldman Sachs maintains Moderna at Neutral, raises price target to $195 from $137

What happened

Goldman Sachs kept its rating on Moderna at Neutral and raised its price target to $195 from $137. The new target is 42.3% higher than the previous one, but the article says it implies 23.3% downside from Moderna’s November 6 closing price of $254.19.

Confirmed

Global impact / market context

The higher target signals that Goldman Sachs sees more value in Moderna than before, but its Neutral rating and implied downside indicate the target remains below the cited closing price. If investors use analyst targets to guide buying or selling, this view could influence demand for Moderna shares.

Analyst inference

Recent analyst views differ substantially: the article lists targets from $90 to $305 across four notes published in the past 30 days. That spread shows uncertainty in analysts’ assessments; the Goldman target is one estimate, not a company forecast or guaranteed share price.

Confirmed

What to watch

1. Compare later analyst updates with Goldman Sachs’s $195 target and Neutral rating to see whether analysts revise their views or continue to differ widely. Analyst inference
2. Check whether Moderna’s share price moves toward or away from the target; the article’s stated 23.3% downside is measured from the November 6 close. Analyst inference
3. Watch for company developments that could affect future revenue or costs, since the supplied article gives no business results or reasons behind Goldman Sachs’s revised target. Analyst inference

Evidence

• Original source link unavailable